Techcyte began as an idea to classify white blood cells using computer vision from Dr. Mohamed Salama that was purchased by Ralph Yarro in a technology transfer from the University of Utah in 2013. Since that initial idea, Techcyte has led the cellular digital pathology revolution by combining the knowledge and skills of a lab professional or pathologist with the latest deep learning technologies to provide the healthcare industries with digital diagnostic solutions.
We believe that individual cells hold clues to diagnosing disease. By analyzing cell morphology, phenotypic characteristics can reveal genotype, conditions and diseases, getting us closer to providing precision medicine.
Research and Drug Development
Techcyte is poised to address some of the most challenging problems facing the research and pharmaceutical industries. Using our AI platform and labeled data, Techcyte can create a custom, scalable solution to find the most critical research and drug development questions.
Clinical & Lab Diagnostic Testing
Techcyte’s platform uses deep learning image analysis to assist the lab professional or pathologist in making critical diagnostic decisions. By partnering with laboratories, we’re making the best-possible AI-powered digital diagnostic tests to assist with diagnosis.
We’re passionate about making healthcare more affordable and accessible to all, especially those in developing countries. Become our partner in delivering low-cost solutions to those that need it most.
To push the envelope of possibilities we’ve partnered with and are advised by world-class pathologists and labs.
Dr. Mohamed E. Salama, MD
Professor, Mayo Clinic School of Medicine Department of Laboratory Medicine and Pathology, Division of Hematopathology
Dr. Salama is a professor of pathology, chief of hematopathology, and director of the Hematopathology Fellowship Program at the University of Utah School of Medicine. Dr. Salama received his MD from Cairo University and completed a hematopathology fellowship at the University of New Mexico and a surgical pathology fellowship at Stanford University. He is certified by the American Board of Pathology in anatomic pathology and hematopathology. His areas of interest span all aspects of hematopathology, including morphology, specialized studies of bone marrow and lymph node, and digital pathology.
Michael A. Aicher, MBA
President, Alveo Technologies
Signatures (ASX: GSS), a company providing innovative molecular diagnostics solutions, serves on the Board of Directors for Fabric Genomics, which analyses and interprets genomic information and was a Board member of Ariosa, a prenatal testing molecular diagnostics company until its acquisition by Roche in 2015. Mike co-founded and served as National Genetics Institute’s (NGI) CEO from 1991 to 2012. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NASDAQ: LH) in 2000, where he ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue. He holds a Bachelor of Science in Business Administration from the University of Redlands, a Master of Business Administration in Economics from Columbus University and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.
Angélica B. Rodríguez, MD
Tecnológico de Monterrey
Dr. Rodríguez received her Doctor of Anatomic Pathology degree from the Tecnológico de Monterrey School of Medicine. Her vast medical training includes internships, rotations, and professional experience at the University of Texas, University of California San Diego, University of Vermont, and UNAM – Hospital General de Mexico. She has a wide range of pathology expertise, including oncopathology, cytopathology, dermatopathology, surgical pathology, digital pathology, and autopsy. Dr. Rodríguez also founded and directs a private practice pathology lab in Zacatecas, Mexico.
Kyl Wilson, JS, MBA
BroadOak Capital Partners
Kyle Wilson is a Partner at BroadOak Captial partners and leads the firm’s M&A advisory activities. With over 20 years of investment banking experience, Kyle’s background includes broad transaction experience in both capital formation and mergers and acquisitions. Kyle joined BroadOak in 2011 and built the firm’s San Francisco office. Prior to BroadOak, Kyle was a Principal at
Canaccord Genuity where he led the tools and diagnostics team and completed over $1.4 billion in life sciences transactions. Kyle holds a B.S. in Business Administration, a Juris Doctorate and M.B.A., all from the University of Oklahoma.
David W. Gardiner DVM, MS, Dipl. ACVP
Animal Reference Pathology
Dr. Gardiner received his Doctor of Veterinary Medicine (DVM) degree from Cornell University and completed his veterinary anatomic pathology residency and Masters of Science (MS) degree at Colorado State University. Dr Gardiner is board certified in veterinary anatomic pathology by the American College of Veterinary Pathologists. Prior to working at Animal Reference Pathology, Dr Gardiner served as the regional head of anatomic pathology for Canada and the western United States for IDEXX Laboratories.
John Haines, Ph.D.
Union College, Russell-Sage College
Former New York State Mycologist, and Curator Emeritus of Mycology at the New York State Museum.
He has done extensive research on airborne fungus spores, building molds, molds associated with asthma, and fungi in the composing process. Dr. Haines has taught mycology at Union College and Russell-Sage College and has run numerous training courses on spore identification in New York, the US, and around the world.